A new pancreatic cancer drug, Daraxonrasib, nearly doubled survival time in Phase 3 trial. Patients receiving it survived a median of 13.2 months compared to 6.7 months on standard chemotherapy, with all participants having previously undergone at least one chemotherapy treatment. The daily pill targets RAS gene-linked cancer signals and harmful mutations found in over 90% of pancreatic cancers.